Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LIM21
- Development stage
- Preclinical
- Lead developer
- Limno Pharma
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
LIM21 is a small molecule drug candidate developed by Limnopharma for the treatment of retinal degenerative diseases, primarily retinitis pigmentosa (RP) and dry age-related macular degeneration (dry-AMD). It is a chemical derivative of natural products, designed as a new chemical entity with neuroprotective, antioxidant, and anti-inflammatory properties. LIM21 modulates the activity of a key epigenetic metabolic regulator involved in aging, inflammation, and apoptosis—mechanisms relevant to retinal degeneration. Preclinical studies have demonstrated efficacy in animal models for RP and dry-AMD. The drug is not gene therapy-based and may be suitable for broad patient populations with these conditions.
Beyond the preview
Go deeper on LIM21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LIM21.